<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091906</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-CTA101-PBMC</org_study_id>
    <nct_id>NCT04091906</nct_id>
  </id_info>
  <brief_title>PBMC Donation in UCAR-T Cells</brief_title>
  <official_title>Peripheral Blood Mononuclear Cell Donation Protocol for Tumor Immunotherapy Study of UCAR-T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Bioheng Biotech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral blood mononuclear cell donation protocol for tumor immunotherapy study of UCAR-T&#xD;
      cells&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collect blood samples</measure>
    <time_frame>Baseline</time_frame>
    <description>Collect blood samples (whole blood and PBMC) from healthy donors for the development and production of UCAR-T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect blood samples</measure>
    <time_frame>Baseline</time_frame>
    <description>Collect blood samples (whole blood) for pre-preparation of autologous CAR-T cells, comparation with UCAR-T products, exploration of the differences in cell expansion and function between UCAR-T and autologous CAR-T, and pre-experiments in the development of various test methodologies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral Blood Mononuclear Cell Donation</condition>
  <arm_group>
    <arm_group_label>Healthy donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral blood mononuclear cell apheresis</intervention_name>
    <description>Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells</description>
    <arm_group_label>Healthy donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18-40 years, no donation reaction in the past;&#xD;
&#xD;
          2. Weight: male ≥ 50 kg, female ≥ 45 kg, and 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2;&#xD;
&#xD;
          3. Blood pressure:&#xD;
&#xD;
        12.0 Kpa (90 mmHg) ≤ systolic pressure﹤18.7 Kpa (140 mmHg) 8.0 Kpa (60 mmHg) ≤ diastolic&#xD;
        pressure﹤12.0 Kpa (90 mmHg) Pulse pressure ≥ 4.0Kpa (30mmHg); 4) Pulse: 60/min to 100/min.&#xD;
        Athletes with high endurance ≥ 50/min, with regular rhythm; 5) Temperature: 36.3-37.2℃&#xD;
        (oral temperature); 6) Generally in good condition: no damage to important organs such as&#xD;
        heart, lung, liver and kidney; no severe or uncontrolled infection; no history of severe&#xD;
        mental disorders; 7) Clinical examination should meet the following criteria:&#xD;
&#xD;
          1. Hemoglobinometry: male ≥ 120g/L; female ≥ 110g/L. If using copper sulfate method: male&#xD;
             ≥ 1.0520, female ≥ 1.0510&#xD;
&#xD;
          2. White blood cell (WBC) test: ≥4×109/L&#xD;
&#xD;
          3. Alanine aminotransferase (ALT) ≤40U/L (Rate method), ≤25U/L (Reitman-Frankel method)&#xD;
&#xD;
          4. Hepatitis B virus surface antigen (HBsAg) negative&#xD;
&#xD;
          5. Hepatitis C virus antibody (HCV antibody) negative&#xD;
&#xD;
          6. Human immunodeficiency virus antibody (HIV-1 and HIV-2 antibody) negative&#xD;
&#xD;
          7. Syphilis negative&#xD;
&#xD;
          8. Cytomegalovirus antibody (CMV antibody) negative&#xD;
&#xD;
          9. Epstein-Barr virus antibody (EBV antibody) negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Donors are ineligible to donate PBMC under the following circumstances:&#xD;
&#xD;
        1) Valetudinarian, with frequent dizziness, giddiness, tinnitus, hemophobia, fear of&#xD;
        needles, faint, and Meniere's disease; 2) Sexually transmitted diseases (STDs), leprosy,&#xD;
        AIDS, and HIV-1, HIV-2, CMV, EBV antibody positive; 3) History of liver diseases, HBsAg&#xD;
        positive and HCV antibody positive. 1 year after the clinical cure of hepatitis A, normal&#xD;
        ALT test results at 1 month interval for 3 consecutive times; 4) Relapsed allergic&#xD;
        diseases, urticaria, bronchial asthma and drug allergies (Donors with simple urticaria who&#xD;
        are not in acute attack are eligible to donate PBMC); 5) Pulmonary tuberculosis, renal&#xD;
        tuberculosis, lymph node tuberculosis and bone tuberculosis; 6) Cardiovascular disease and&#xD;
        history, various heart diseases, hypertension, hypotension, myocarditis and&#xD;
        thrombophlebitis; 7) Respiratory diseases (including chronic bronchitis, emphysema,&#xD;
        bronchiectasis and pulmonary insufficiency); 8) Digestive system diseases (e.g. severe&#xD;
        gastric and duodenal ulcers, chronic gastroenteritis and chronic pancreatitis); 9) Urinary&#xD;
        system diseases (e.g. acute and chronic nephritis, chronic urinary system infection,&#xD;
        nephrotic syndrome, acute and chronic renal insufficiency, etc.); 10) Various hematological&#xD;
        diseases (including anemia, leukemia, polycythemia vera and various hemorrhagic and&#xD;
        coagulative diseases); 11) Endocrine diseases or metabolic disorders (e.g. hyperthyroidism,&#xD;
        acromegaly, diabetes insipidus, diabetes mellitus, etc.); 12) Organic nervous system&#xD;
        diseases or psychoses (e.g. encephalitis, sequelae of brain trauma, epilepsy,&#xD;
        schizophrenia, hysteria, severe neurasthenia, etc.); 13) Parasitic diseases and endemic&#xD;
        diseases (e.g. kala-azar, schistosomiasis, filariasis, hookworm disease, taeniasis,&#xD;
        paragonimiasis, Keshan disease, Kaschin-Beck disease, etc.); 14) Malignancies and benign&#xD;
        tumors affecting health; 15) History of haematological malignancies (e.g. leukaemia,&#xD;
        lymphoma, myeloma), history of malignancies known to be associated with viraemic conditions&#xD;
        (except for carcinoma in situ of the cervix). For other cancers, the donors should have&#xD;
        fully recovered with no expectation of recurrence (i.e. cured) and the following conditions&#xD;
        apply:&#xD;
&#xD;
          1. for cancers with negligible metastatic potential (e.g. basal cell carcinoma and&#xD;
             carcinoma in situ of the cervix), the donors may be accepted immediately following&#xD;
             successful removal and cure&#xD;
&#xD;
          2. for all other cancers, at least 5 years should have elapsed since completion of active&#xD;
             treatment 16) Undergone resection of stomach, kidney, gallbladder, spleen, lung and&#xD;
             other important organs; 17) Exposure to harmful substances or radioactive substances&#xD;
             (except for clinical radiology); 18) High-risk groups susceptible to HIV infection,&#xD;
             such as drug users, homosexuals and people with multiple sexual partners; 19)&#xD;
             Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt disease (vCJD), family history,&#xD;
             and treatment with human and animal pituitary-derived substances (e.g. growth hormone,&#xD;
             gonadotropin, thyrotropin, etc.). Organ transplantation recipients (including cornea,&#xD;
             bone marrow, dura mater) may be exposed to bovine spongiform encephalopathy (BSE) and&#xD;
             vCJD; 20) Chronic skin diseases, especially infectious, allergic and inflammatory&#xD;
             systemic skin diseases (e.g. favus, generalized eczema, systemic psoriasis, etc.); 21)&#xD;
             Autoimmune diseases and collagenosis (e.g. systemic lupus erythematosus,&#xD;
             dermatomyositis, scleroderma, etc.); 22) Bitten by animals carrying rabies virus; 23)&#xD;
             Other diseases or conditions in which donors are ineligible to donate PBMC in the&#xD;
             opinion of physicians;&#xD;
&#xD;
        Donors should be deferred for the time being under the following circumstances:&#xD;
&#xD;
          1. Tooth extraction or other minor surgery within half a month;&#xD;
&#xD;
          2. 3 days before or after menstruation, menstrual disorders, pregnancy, less than 6&#xD;
             months after abortion, less than 1 year after delivery and lactation;&#xD;
&#xD;
          3. Less than 1 week after the recovery of cold and acute gastroenteritis, less than 1&#xD;
             month after the cure of acute urinary system infection, and less than half a year&#xD;
             after the cure of pneumonia;&#xD;
&#xD;
          4. Donors from high-risk areas of infectious diseases as prescribed by certain infectious&#xD;
             diseases and epidemic prevention departments. Less than half a year after the cure of&#xD;
             dysentery, less than 1 year after the cure of typhoid fever and brucellosis, history&#xD;
             of malaria within 3 years;&#xD;
&#xD;
          5. Within 2 years after blood transfusion treatment;&#xD;
&#xD;
          6. Less than 1 year after tattoo, injuries or contaminated wounds caused by equipment&#xD;
             contaminated by blood or tissue fluid;&#xD;
&#xD;
          7. Close contact history with patients with infectious diseases: within the longest&#xD;
             incubation period of the disease after the date of contact;&#xD;
&#xD;
          8. Recipients of animal serum products: within 4 weeks after the last injection;&#xD;
&#xD;
          9. Recipients of hepatitis B immunoglobulin (HBIG) injection: within 1 year;&#xD;
&#xD;
        Provisions for PBMC collection after immunization:&#xD;
&#xD;
        1) Asymptomatic donors who have recently received immunization may donate PBMC only after&#xD;
        the following period of time: 2 weeks after the last immunization of measles, mumps, yellow&#xD;
        fever, poliomyelitis and live attenuated hepatitis A vaccine, 4 weeks after the last&#xD;
        immunization of live rubella vaccine and rabies vaccine;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianyong Li, Ph.D.</last_name>
    <phone>025-83718836</phone>
    <email>lijianyonglm@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li, PhD</last_name>
      <email>lijianyonglm@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

